Cy­to­ki­net­ics ax­es lead drug af­ter it im­plodes in a PhI­II mus­cle tri­al for ALS, shares crater

Cy­to­ki­net­ics $CYTK lead mus­cle drug has crashed in a Phase III study for ALS.

The biotech re­port­ed this morn­ing that tirasem­tiv, de­signed to amp up the mus­cles of sick pa­tients, failed to hit the pri­ma­ry end­point on what’s called slow vi­tal ca­pac­i­ty, which mea­sures how much air can be ex­haled. And now the ther­a­py is be­ing shelved as the biotech’s stock craters, plung­ing more than 30% Tues­day morn­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER